It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...

The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach ...

RevivBio, a trailblazing biotech company Redefining Biologics and Biosensors development, welcomes Dr. Ron Meeusen to its Board of Directors. Dr. Meeusen is a renowned leader in biotechnology, with a ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

Job cuts at home-grown pharma companies like Arvinas and RallyBio and federal policies challenge CT biotech 'ecosystem' that ...

Backed by major investors, Volare’s new facility will turn food waste into sustainable insect protein and help boost Europe’s ...

Cambridge biotech Nuclera has agreed a collaboration with Danaher company and international life sciences leader Cytiva – ...

Goldman Sachs Global Healthcare Conference on Wednesday, June 11, 2025 at 2:40 p.m. ET ...

At the recent F&A Next conference in Wageningen, the Feike Sijbesma Sustainable Innovation Award 2025 was granted to two ...

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...